Kiadis Pharma Announces Positive Clinical Results For ATIR(TM) In Mismatched Bone Marrow Transplantations
Biopharmaceutical company Kiadis Pharma announces that it has successfully completed treatment of the last patient on its ATIR(TM) phase I/II clinical trial. ATIR(TM), a donor lymphocyte cell based product, is under development to prevent acute Graft versus Host Disease (GvHD) and allow early immune reconstitution following a mismatched bone marrow transplantation.
More: continued here
Filed under: Bones on December 6th, 2008